+ Watch MYRX
on My Watchlist
Lead drug candidate suspended...this is a cash play. Following the just recently announced termination of development of Azixa, there was the expected sell-off, but there wasn't a huge drop in price and it has recovered to pre-announcement levels, so it would appear that the market is being very mindful of their cash position. The remaining drugs in the pipeline aren't terribly advanced in development, and it will be interesting to see where the newly appointed CEO will take Myrexis from here.
Technically oversold with a nice balance sheet. Recent insider buys don't hurt either.
The are a buy out target
The pipeline looks nice, but... what do I know about these things? No debt, decent amount of cash on hand. For a speculative play on an emerging biotech, you just have to follow the trend sometimes. Looks like it's trending up, to me.
lots of cash
Valued below cash on hand. Jumping ahead of ZZLangerhans based on his excellent may 25 blog. Going long at $4.10 prox.
focus on Azixa trials
I just think that 100millUSD is too low a valuation for a pipeline of potentially blockbuster drugs. Yes, they could dilute their shares away and trade for 10c eventually, but that is a 100% downside vs. a 1,000% upside. I am fine with those odds because overall the biotech index trades upwards. I suspect that if you were to remove the post success biotechs from the index, the group would be doing even better. So invest pre-success and cast a wide net.
Trading at less than cash and pipeline is worth more than $100 million anyway.I'm not sure about the Javelin gamble makes much sense, but at least it didn't use cash to get it.
Very undevalued. Market value $130 million, cash $181 million. 3 drus in clic; 3 preclinic.
Taking my chances that one of their big boppers will be a winner
What everyone else said
Company has no debt and 180millon dollars in the bank and a very intersting pipe line, that we should get some info by the end of year. The market cap is 110.20 millon and more cash than market value a no brainer
Biotech trading for less than their cash
bought in real life at $4.50 and $4.70... definitely one of the top stocks in my real portfolio.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions